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Acceptance checklist for clinical effectiveness
pilot trials: a systematic approach
Georgina Charlesworth1,2*, Karen Burnell3, Juanita Hoe4, Martin Orrell2,4 and Ian Russell5
Abstract
Conducting a pilot trial is important in preparing for, and justifying investment in, the ensuing larger trial. Pilot trials
using the same design and methods as the subsequent main trial are ethically and financially advantageous
especially when pilot and main trial data can be pooled. For explanatory trials in which internal validity is
paramount, there is little room for variation of methods between the pilot and main trial. For pragmatic trials,
where generalisability or external validity is key, greater flexibility is written into trial protocols to allow for ‘real life’
variation in procedures. We describe the development of a checklist for use in decision-making on whether pilot
data can be carried forward to the main trial dataset without compromising trial integrity. We illustrate the use of
the checklist using a pragmatic trial of psychosocial interventions for family carers of people with dementia as a
case study.
Keywords: Pilot trial, Internal pilot, Randomized controlled trial, Feasibility, CONSORT, ACCEPT, SHIELD,
Carer supporter programme
Introduction
Pilot studies focus on the science, process, management
and resources of planned studies [1]. Their purpose is to
increase the likelihood of success of interventions in
subsequent larger studies by ensuring they are appropri-
ate and effective in practice [2-4]. Pilot studies help to
justify the investment of money and time in those subse-
quent studies [5]. Hence they are often a requirement of
funding bodies [6].
The aims of this article are to: (1) consider the nature and
extent of permissible changes to procedures between the
pilot and main trial without breaching methodological in-
tegrity (2) propose a checklist of areas where amendments
to trial procedures may arise (3) illustrate the process of de-
ciding whether to accept data from pilots into main trials.
Background
Pilot trials have been defined as “miniature versions of
full trials conducted to ensure the detailed design,
methods and procedures are all robust and fit for pur-
pose” [7]. The term ‘pilot trial’ should not be confused
with the term ‘pilot study’. The latter has been used syn-
onymously with the term ‘feasibility study’ in which trial
processes, resources, management and scientific factors
are scrutinised in order to facilitate the planning of
large-scale investigations [8].
Recent reviews have highlighted a variety of situations
where the term ‘pilot trial’ has been used, or, some would
argue, misused. For example: as a substitute for hypothesis-
testing studies rather than being preparation for a full trial;
to make inadequately powered studies sound more attract-
ive to publishers; and, to report on outcomes rather than
design, methods and procedures [2,9,10].
Having established the definition of pilot trials as ‘full
trials in miniature’ we next need to define the common
subtypes of pilot trial, namely the internal and external
pilot. Lancaster and colleagues define ‘external’ pilot trials
as ‘stand alone’ pieces of work, planned and conducted in-
dependently of the main trial [6]. In contrast ‘internal’ pilot
trials are set up with the intention of being incorporated
into the main trial. Lancaster et al. described the purpose
of pilot trials as being limited to collection of data for sam-
ple size re-calculation such that pilots do not allow for the
pre-testing of the feasibility of other factors relating to the
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trial. However, we suggest that a degree of feasibility testing
should be allowable in the internal pilots of pragmatic
trials, and that scientific integrity can be maintained as
long as the degree of variation to procedure is within
the limits of variation likely to be seen in the full prag-
matic trial. Treweek and Zwarenstein have argued that
“if we want evidence from trials to be used in clinical
practice and policy, trialists should make every effort to
make their trials widely applicable, which means trials
should be pragmatic in attitude” [11]. It would seem
pragmatic to extend this attitude to internal pilots.
There are considerable advantages to carrying data for-
ward from pilot trials, including: reduced cost, reduced
burden on study populations, increased numbers of par-
ticipants in the full trial, and maintenance of momentum
from pilot to main trial [12]. However, the scientific in-
tegrity of a trial requires that the aims and methods of
the pilot study, if not its geographical extent, match
those of the full trial. If ‘feed forward’ of data is to take
place from pilot to full trial, those charged with oversee-
ing the adequacy of trial conduct, for example Trial
Steering Committees (TSCs) and Data Monitoring and
Ethics Committees (DMECs) need a structured ap-
proach to identifying and documenting any protocol
developments that take place after the start of the planned
internal pilot.
Within the literature on trial methodology, there are
existing tools for reporting pilot trials and for defining
‘success’ in pilot studies. For example, Thabane et al. [8]
highlight the importance of assessing the success of a
pilot study based on predefined criteria, typically relating
to recruiting and retaining participants. Their approach
is valuable when assessing feasibility and acceptability of
study methods, but is not focussed on decision-making
relating to the appropriateness or otherwise of carrying
data forward to the main trial dataset. They suggest four
potential outcomes for pilot studies: stop; continue but
modify protocol (feasible with modifications); continue
without modifications but monitor closely (feasible with
close monitoring); or continue without modification
(feasible as is). Where a decision has been made to stop
then there should be no carry forward of data, whereas
decisions to continue without modification would allow
for data carry-forward. Within the category of ‘continue
but modify protocol’ (feasible with modifications) it may
or may not be appropriate to carry data forward to the
full trial. It is within this category that further consider-
ation is required regarding the nature of modifications
and their potential impact on the integrity of the final
dataset.
In considering approaches to the ‘pooling’ of pilot data
and full trial data, we have also considered ‘adaptive trials’,
defined as “a design that allows modifications to be made
to a trial’s design or statistical procedures during its
conduct with the purpose of efficiently identifying clinical
risks/benefits of a new intervention or to increase the
probability of success of clinical development” [13]. In
adaptive trials the design, methods and procedures of
extended internal pilots of trials are assessed mid-trial
with a view to implementing pre-defined change to design
or statistical procedures whilst the trial is running. The
approach is based on potential amendments being identi-
fied prior to the trial and cannot be used to respond to
issues that are identified only during the course of the
pilot. Also, difficulties arise where interim analysis are part
of the review method as analysis of early data can bias the
ongoing trial by focusing on whether the intervention is
effective such that findings influence design rather than
the reverse [14,15].
In the absence of existing recommendations for decision-
making on the acceptability of carrying forward pilot data
into the full trial dataset of pragmatic trials, we wanted to
develop a method of recording design modifications made
during the pilot phase. By creating a method for systematic-
ally documenting amendments, and for recording decisions
on the significance of these amendments, we intended to
provide a body of information that trialists could use to
make an informed decision. Although a wide range of deci-
sions is possible, we are envisaging three categories:
Decision A: unequivocal acceptance of pilot data:
when the pilot confirms that design and methods are
feasible and appropriate except perhaps for minor de-
tails. Pilot data can be carried forward to the main trial
dataset.
Decision B: conditional acceptance: when the pilot con-
firms that design and methods are feasible and appropri-
ate in principle but need specific refinements (decision
B1); decision on whether to include pilot data in full trial
dataset must be delayed until the variation in procedures
for the full pragmatic trial is known, including both within
and between site differences (decision B2).
Decision C: non-acceptance of pilot data: when a first
pilot identifies the need for a substantial change that the
pilot did not assess, even implicitly. Data from the pilot
cannot be carried forward to the main trial dataset.
The place of these decision points within the ‘flow’ of
a trial are illustrated in Figure 1.
Two elements of the decision options above require
a ‘judgement call’ by research leads or monitoring
committees; for decision ‘A’ how ‘minor’ do details
need to be? and; for decision ‘B’ how much proce-
dural variation is acceptable within a full trial? The
definitions of ‘minor’ versus ‘substantial’ amendments
have been drawn up bodies charged with the ethical
scrutiny of projects, and may prove useful in the deci-
sion making process. The degree of acceptable variation in
research procedures and intervention provision within and
between the sites of pragmatic trials will vary depending
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on the degree of heterogeneity ‘on the ground’, and the de-
gree to which such variation can be reasonably reduced
within ‘natural’ or ‘service-dictated’ provision. Methods for
monitoring pilots therefore need to go beyond the issues of
recruitment and retention of participants to cover all
aspects of the trial.
Development of acceptance checklist for clinical
effectiveness pilot trials (ACCEPT)
1) To ensure comprehensive coverage of pilot trial
procedures we drew up a list of components
derived from the CONSORT 2010 statement
[16].
2) For each trial component we considered potential
methods of monitoring procedures and potential
outcomes from that monitoring process
(see Table 1) covering:
 Feasibility and appropriateness of the trial design.
 Feasibility and appropriateness of the mechanics,
management and safety of interventions.
 Acceptability and efficiency of implementing the
research procedures.
The table of proposed trial components, monitoring
methods and monitoring outcomes formed the draft
ACCEPT document.
3) Based on the draft checklist we planned and tested
methods of monitoring, and recorded outcomes of
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Figure 1 Flow chart of decision points in pilot trials.
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Table 1 Acceptance checklist for clinical effectiveness pilot trials (ACCEPT): trial components, exemplar monitoring methods and exemplar outcomes
Component of trial Monitoring methods (exemplars) Amend? Outcomes (exemplars)
Trial design Review research protocol especially balance of scientific &
practical needs
Yes/No Amend trial design & dependent components. Submit amendment
to Research Ethics Committee
Sample size Test assumptions within protocol on: number of (active) centres;
recruitment rates; retention rates; & SD of primary outcomes
Yes/No Revise if necessary: sample size calculation; trial period; &
funding
Interventions Clinical governance Assess compliance with: formal training in intervention; Health &
Safety regulations; & other clinical governance requirements
Yes/No Enhance formal training of intervention providers
Intervention fidelity Measure & assess adherence to intervention manual by video,
observation or audio
Yes/No Enhance clinical supervision of intervention providers
Participants Recruitment strategy Assess: flows of participants; cost & productivity of each route Yes/No Refine recruitment strategy, generally & locally
Eligibility criteria Assess: characteristics of sample; barriers to recruitment; update
of intervention





Consult participants & refusers Yes/No Refine PIS especially to address frequently asked questions
Taking informed
consent
Audit consent documentation. Measure & assess adherence to consent
procedures by video, observation or audio
Yes/No Enhance training of research team
Randomisation process Check quality especially: accessibility by researchers; validity of
CONSORT flowchart; & accuracy of stratifying variables
Yes/No Refine: randomisation procedure & parameters; & training of
research team
Blinding Check whether assessors can predict individual allocations. Test
whether unblinded researchers can keep other researchers blind
Yes/No Refine blinding procedures, e.g. by reallocating responsibilities within
research team
Data Data collection Assess adherence to interview schedules & fieldwork handbook,
including duration of assessments, by video, observation or audio
Yes/No Refine schedules to reduce assessment burden. Enhance training of
research team
Data quality Test missing data procedures within draft analysis plan Yes/No Refine data collection tools & missing data procedures





Enable quality assurance officer (QAO) to test adherence as
widely as possible
Yes/No Refine: protocol; quality assurance plan & training of team
Adverse events (AE) QAO to test procedures for: reporting AEs; assessing severity,
causality & expectedness monitor at management group; report to
DMEC
Yes/No Refine AE reporting & assessment procedures
Health & Safety Test H&S procedures, e.g. for lone working Yes/No Refine H&S procedures
Data analysis Test draft analysis plan on pilot data Yes/No Refine analysis plan to address research aims in full
Trial management Review role descriptions of research team. Review remits of trial
management group, trial research team etc.
Yes/No Review role descriptions of research team. Refine roles e.g. if










































































interventions for family carers of people with
dementia [17]. We gathered evidence on design,
methods and procedures from research
participants, research staff, the providers of
interventions (both experimental and control) and
recipients of those interventions. The trial research
team and trial management group, including
grantholders and methodologists, DMEC and TSC,
reviewed the recorded evidence. On the basis of the
monitoring outcomes, decisions were made on
whether pilot data could be carried forward to the
main trial. (See following ‘Case Study’)
4) We wrote about the checklist, termed Acceptance
Checklist for Clinical Effectiveness Pilot Trials
(ACCEPT), and submitted the description for peer
review.
5) On the basis of feedback from peer reviewers we
reviewed our explanation of the rationale to place
ACCEPT within an international context, and
clarified its proposed use with the particular focus
on carry forward of data from pilot to main trial.
Case-study – Carer Supporter Programme (CSP)
The CSP trial is part of the SHIELD research programme
into psychosocial interventions in dementia funded by the
National Institute of Health Research. The trial compares
four interventions: one-to-one peer support for family carers
of people with dementia (CSP); large group reminiscence
therapy for people with dementia and their family carers
(Remembering Yesterday Caring Today – RYCT); CSP and
RYCT in combination; and treatment as usual – neither
CSP nor RYCT [17].
The pilot trial ran in two Boroughs of London, England.
In the first site we focused on appropriateness and accept-
ability of procedures whereas the focus in the second site
was on logistics and timing of the interventions in relation
to the timetable for recruitment and research interviewing
procedures. We devised monitoring methods in accord-
ance with our draft checklist, and systematically recorded
the outcomes of these alongside recording of the implica-
tions for the main trial.
Drawing from the trial components of eligibility criteria
(a subcomponent of ‘participants’), trial design, interven-
tion fidelity (a subcomponent of ‘interventions’) and data
quality, we provide examples of the monitoring methods
used, the outcome of the monitoring process and decisions
made on the potential pooling of pilot and full trial data.
Eligibility criteria
Eligible participants were people with primary progressive
dementia and their family carers. Early feedback from re-
cruiters identified uncertainty in assessing eligibility when
presentations were a-typical, where there were comorbidities
such as stroke, head injury or movement disorders, and
where potential participants without a formal diagnosis of
dementia were nevertheless in receipt of dementia-related
treatments and services. During the pilot we reviewed and
clarified the screening tool, and encouraged discussion with
clinical researchers where there was uncertainty. Eligibility
of clients with a-typical presentations was discussed on a
case-by case basis throughout the trial, but the eligibility of
most potential participants could be determined on the basis
of the original screening questions. We therefore concluded
that changes to the assessment of eligibility criteria could be
considered minor and were not a barrier to the carry for-
ward of data from the pilot to full trial.
Trial design
The two psychosocial interventions had different delivery
formats: CSP focused on individual carers while RYCT fo-
cused on groups of people with dementia and their carers.
We therefore needed a trial design that allowed simultan-
eous delivery of individual interventions and a group
programme such that a random sample of participants re-
ceived the combined intervention. We devised a 2-stage
randomisation process in which each participant was
randomised individually immediately post-baseline assess-
ment to either CSP intervention or control, and subse-
quently entered into a group randomisation process to
either RYCT or control. Experience in the first pilot site
was that the time-lag between the first and last individual
randomisation was such that the proposed timetable for
follow-up interviews was put in jeopardy. In the second
pilot the individual intervention was yoked to the group
timetable and procedures tightened such no potential par-
ticipants undertook initial assessments until a minimum
cohort size had been identified as willing and eligible. In
the main trial there continued to be variation in the time
difference between baseline assessment and the start of
intervention, and between the end of intervention and
final follow-up interview. The monitoring data will allow
comparison between arms of the trial and a decision on
whether to include pilot data in the final dataset will need
to be made once final follow-ups are complete.
Also relating to trial design, feedback from researchers in
the first pilot site alerted the research team to participants
expressing greater interest in the individual support inter-
vention than the group intervention. This had implications
for intervention uptake and the feasibility of the group
intervention sessions. Prompt discussion with the trial
methodologists before the group randomisation in the first
pilot site enabled us to adjust randomisation ratios for the
group randomisation from 1:1 to 2:1 (RYCT:control). The
revised randomisation ratios facilitated adequate RYCT
group size in subsequent rounds of recruitment and inter-
vention. If this modification had not been made prior to the
first group randomisation, data from the first pilot site
could not have been carried forward to the main trial
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dataset as the trial design of the pilot would have differed
significantly from that used in the main trial.
Intervention fidelity
In order to ensure intervention fidelity, experienced clini-
cians in the research team were closely involved in the
set up and provision of interventions at the pilot stage.
Recording systems on aspects of intervention fidelity
were devised and tested during the pilot and then
implemented fully during the full trial. Variation of inter-
vention provision was greater during the full trial than it
had been in the pilot sites due to differences in the
funding and organisation of services in each geographical
area. For example, in the trial sites the RYCT interven-
tion was delivered with involvement from National
Health Service (NHS) employees and the Carer Sup-
porter intervention provided by organisations within the
voluntary and charitable sector. This model of interven-
tion provision was replicated for most rounds of recruit-
ment and intervention for the full trial but in some
additional sites both interventions were provided by the
NHS and in one further site a voluntary/charitable sector
organisation provided both. The same RYCT group
trainer was used throughout the trial, and, although
minor details of the content of training were amended
through the course of the trial, the core of the training
manual was consistent throughout the pilot and full trial.
Intervention fidelity was higher in the pilot sites, but fell
within the ‘envelope’ of variation seen across the full trial.
A decision was therefore made that pilot data should not
be held back from being pooled with the main trial
dataset on grounds of variation in intervention fidelity.
Data quality
An early audit of the completeness of baseline data in
the first pilot site enabled us to identify systematically
missing data. The main issue was the formatting of data
collection tools, which allowed researchers or respon-
dents to misinterpret question routing and omit ques-
tions. Hence we reformatted these tools and re-trained
researchers. The corresponding audit in the second pilot
site showed a reduction in missing data. Thus early iden-
tification of data collection issues, and immediate estab-
lishment of monitoring, enhanced the quality of the
dataset throughout the trial, and kept the proportion of
missing data to a minimum. A high proportion of missing
data would have led to a decision to exclude pilot data
from the main trial dataset.
Conclusions
Using ACCEPT enabled us to systematically record trial
monitoring methods, and record challenges and changes
to the design, methods and procedures of the trial, to-
gether with working solutions for a pragmatic trial of
two complex psychosocial interventions. Transparent re-
cording of monitoring methods and outcomes facilitated
decision-making on whether data could be appropriately
pooled with the main trial dataset.
Consistent with guidelines for reporting pilot trials [8],
we have based ACCEPT on the trial elements highlighted
in the CONSORT 2010 statement [16]. The systematic re-
cording and reporting of monitoring methods and of
changes in, and deviations from, the original protocol is a
requirement of ethical committees and CONSORT
reporting standards [16]. Decisions on whether to ‘carry for-
ward’ data from the pilot trial to the main trial will depend
on the degree of acceptable variation in procedures within
the main trial. This will be influenced by the location of the
trial along the pragmatic-explanatory continuum [18]. The
final decision on inclusion of pilot data may not be made
until after final data collection as although some compo-
nents (e.g. trial design) need only a brief, defined pilot
period, other components (e.g. data analysis) benefit from
an extended pilot period.
In line with guidance for developing health research
reporting guidelines [19], ACCEPT needs testing with
other designs in other contexts. Fortunately the focus on
design, methods and procedures facilitates the tailoring of
ACCEPT to individual trials. Furthermore it permits trac-
king of progress by the trial management group, DMEC
and TSC. Above all ACCEPT provides a systematic basis
for decisions about whether or not a pilot has adequately
tested a trial’s design, methods and procedures, and thus
whether pilot data can be integrated into the main trial.
Abbreviations
ACCEPT: Acceptance checklist for clinical effectiveness pilot trials; AE: Adverse
events; CONSORT: Consolidated standards of reporting trials; CSP: Carer
Supporter programme; DMEC: Data monitoring and ethics committee;
H&S: Health and safety; NHS: National health service; NIHR: National institute
of health research; PIS: Patient information sheet; QAO: Quality assurance
officer; RYCT: Remembering yesterday, caring today; SHIELD: Support at
home: interventions to enhance life in dementia; TSC: Trial steering
committee.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
IR conceived the notion of a pilot acceptance plan. GC and KB developed such
a plan for the CSP pilot trial and implemented it successfully. GC, KB, MO and IR
drafted the paper. All authors commented on successive drafts. GC produced
the final version. All authors read and approved the final manuscript.
Acknowledgements
The Carer Supporter Programme (ISRCTN37956201) is part of the Support at
Home - Interventions to Enhance Life in Dementia (SHIELD) research
programme (Application No. RP-PG-0606-1083) which is funded by the National
Institute for Health Research (NIHR) Programme Grants for Applied Research
funding scheme. The Chief Investigator is Professor Martin Orrell (UCL), and
grantholders are Professors Woods (Bangor), Challis (Manchester), Knapp (LSE),
Moniz-Cook (Hull) and Russell (Swansea), and Dr Charlesworth (UCL).
We thank all those involved in the peer review of ACCEPT.
The views expressed in this publication are those of the authors and not
necessarily those of the NIHR, the NHS or the Department of Health.
Charlesworth et al. BMC Medical Research Methodology 2013, 13:78 Page 6 of 7
http://www.biomedcentral.com/1471-2288/13/78
Author details
1Research Department of Clinical, Educational and Health Psychology,
University College London, 1-19 Torrington Place, London WC1E 7HB, UK.
2Research and Development Department, North East London NHS
Foundation Trust, Goodmayes Hospital, Barley Lane, Ilford, Essex IG3 8XJ,
England. 3School of Health Sciences and Social Work, James Watson (West),
2 King Richard 1st Road, Portsmouth PO1 2FR, England. 4UCL Mental Health
Sciences Unit, University College London, Charles Bell House, 67-73 Riding
House Street, London W1W 7EJ, UK. 5West Wales Organization for Rigorous
Trials in Health, Swansea University College of Medicine, Singleton Park,
Swansea SA2 8PP, Wales.
Received: 22 November 2012 Accepted: 29 May 2013
Published: 13 June 2013
References
1. Van-Teijlingen ER, Hundley V: The importance of pilot studies. Soc Res
Update 2001, 35. [http://sru.soc.surrey.ac.uk/SRU35.html.
2. Leon AC, Davis LL, Kraemer HC: The role and interpretation of pilot
studies in clinical research. J Psychiatr Res 2011, 45:626–629.
3. Rounsaville BJ, Carroll KM: A stage model of behavioural therapies
research: getting started and moving on from Stage I. Clin Psychol Sci
Pract 2001, 8:133–142.
4. Craig N, Dieppe P, Macintyre S, Michie S, Nazareth I, Pettigrew M:
Developing and evaluating complex interventions: the new Medical
Research Council guidance. Brit Med J 2008, 337:a1655.
5. Arnold DM, Burns KEA, Adhikari NKJ, Kho ME, Meade MO, Cook DJ, for the
McMaster Critical Care Interest Group: The design and interpretation of pilot
trials in clinical research in critical care. Crit Care Med 2009, 37S:S69–S74.
6. Lancaster GA, Dodd S, Williamson PR: Design and analysis of pilot studies:
recommendations for good practice. J Eval Clin Pract 2004, 10:307–312.
7. NIHR Health Technology Assessment Programme (NETSCC): Feasibility and
pilot studies. [www.netscc.ac.uk/glossary/index.asp#glos7]
8. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios L, et al: A tutorial on pilot
studies: the what, why and how. BMC Med Res Methodol 2010, 10:1.
9. Arain M, Campbell MJ, Cooper CL, Lancaster GA: What is a pilot or
feasibility study? a review of current practice and editorial policy.
BMC Med Res Methodol 2010, 10:67.
10. Shanyinde M, Pickering RM, Weatherall M: Questions asked and answered
in pilot and feasibility randomized controlled trials. BMC Med Res
Methodol 2011, 11:117.
11. Treweek S, Zwarenstein M: Making trials matter: pragmatic and
explanatory trials and the problem of applicability. Trials 2009, 10:37.
12. Wittes J, Brittain E: The role of internal pilot studies in increasing the
efficiency of clinical trials. Stat Med 1990, 9:65–72.
13. Chow SC, Chang M: Adaptive design methods in clinical trials – a review.
Orphanet J Rare Dis 2008, 3:11.
14. Freidlin B, Korn EL: Release of data from an ongoing randomized clinical trial
for sample size adjustment or planning. Stat Med 2007, 26:4074–4082.
15. Tharmanathan P, Calvert M, Hampton J, Freemantle N: The use of interim
data and data monitoring committee recommendations in randomized
controlled trial reports: frequency, implications and potential sources of
bias. BMC Med Res Methodol 2008, 8:12.
16. Moher D, Hopewell S, Schulz K, Montori V, Gøtzsche PC, Devereaux PJ,
Elbourne D, Egger M, Altman DG: CONSORT 2010 explanation and
elaboration: updated guidelines for reporting parallel group randomised
trials. Brit Med J 2010, 340:c869.
17. Charlesworth G, Burnell K, Beecham J, Hoare Z, Hoe J, Wenborn J,
Knapp M, Russell I, Woods B, Orrell M: Peer support for family carers
of people with dementia, alone or in combination with group
reminiscence in a factorial design: study protocol for a randomised
controlled trial. Trials 2011, 12:205.
18. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG,
Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K: A pragmatic-explanatory
continuum indicator summary (PRECIS): a tool to help trial designers.
Can Med Assoc J 2009, 180:E47.
19. Moher D, Schulz KF, Simera I, Altman DG: Guidance for developers of
health research reporting guidelines. PLoS Med 2010, 7(2):e1000217.
doi:10.1186/1471-2288-13-78
Cite this article as: Charlesworth et al.: Acceptance checklist for clinical
effectiveness pilot trials: a systematic approach. BMC Medical Research
Methodology 2013 13:78.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Charlesworth et al. BMC Medical Research Methodology 2013, 13:78 Page 7 of 7
http://www.biomedcentral.com/1471-2288/13/78
